Vaxart Inc (NASDAQ: VXRT) will enable Altesa to focus on developing and commercializing a clinical-stage broad-spectrum antiviral called capsid-binding VapendavirTM.The above antiviral belongs to Vaxart Inc, and Altesa gets the rights following the company’s agreement to sign a worldwide exclusive license. Altesa to start taking advantage of the license Altesa operates […]